स्विट्ज़रलैंड - जर्मन - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - ombitasvirum, paritaprevirum, ritonavirum - filmtabletten - ombitasvirum 12,5 mg zu ombitasvirum hydricum, paritaprevirum 75 mg zu paritaprevirum dihydricum, ritonavirum 50 mg, excipiens pro compresso dunst. - chronische hepatitis c - synthetika

स्विट्ज़रलैंड - जर्मन - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - dasabuvirum - filmtabletten - dasabuvirum 250 mg dasabuvirum natricum endwerte. dasabuvirum natricum monohydricum 270.26 mg, excipiens pro compresso dunst. - chronische hepatitis c - synthetika

ऑस्ट्रिया - जर्मन - AGES (Agentur für Gesundheit und Ernährungssicherheit)

sandoz gmbh - efavirenz -

यूरोपीय संघ - जर्मन - EMA (European Medicines Agency)

teva b.v. - efavirenz - hiv-infektionen - antivirale mittel zur systemischen anwendung - efavirenz ist indiziert bei der antiviralen kombinationsbehandlung von mit menschlichem immunschwächevirus-1 (hiv-1) infizierten erwachsenen, jugendlichen und kindern ab 3 jahren. efavirenz wurde nicht ausreichend untersucht bei patienten mit fortgeschrittener hiv-erkrankung, nämlich bei patienten mit cd4 zählt < 50 zellen/mm3 oder nach versagen von protease-inhibitor (pi)-haltige therapien. obwohl eine kreuzresistenz von efavirenz mit protease-inhibitoren (pis) noch nicht dokumentiert wurde, gibt es derzeit nur unzureichende daten über die wirksamkeit der nachfolgenden nutzung des pi-basierenden kombinationstherapie nach versagen von regimen mit efavirenz.

जर्मनी - जर्मन - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

accord healthcare b.v. (8182087) - efavirenz - filmtablette - teil 1 - filmtablette; efavirenz (29242) 600 milligramm

जर्मनी - जर्मन - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

medicopharm ag arzneimittel & medikal produkte (8021444) - efavirenz - tablette - teil 1 - tablette; efavirenz (29242) 600 milligramm

जर्मनी - जर्मन - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

h e x a l aktiengesellschaft (3079284) - efavirenz - filmtablette - teil 1 - filmtablette; efavirenz (29242) 600 milligramm

जर्मनी - जर्मन - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

puren pharma gmbh & co. kg (8034441) - efavirenz - filmtablette - teil 1 - filmtablette; efavirenz (29242) 600 milligramm

यूरोपीय संघ - जर्मन - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir - hiv-infektionen - antivirale mittel zur systemischen anwendung - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

यूरोपीय संघ - जर्मन - EMA (European Medicines Agency)

merck sharp dohme ltd - boceprevir - hepatitis c, chronisch - antivirale mittel zur systemischen anwendung - victrelis ist indiziert für die behandlung der chronischen hepatitis c (chc)-genotyp-1-infektion in kombination mit peginterferon alfa und ribavirin bei erwachsenen patienten mit kompensierter lebererkrankung, die zuvor unbehandelten oder nicht gelungen, die bisherige therapie.